Prognostic value of dynamic albumin-to-alkaline phosphatase ratio in limited stage small-cell lung cancer

• Published in: Future oncology (London, England) Vol. 15; no. 9; pp. 995 - 1006
• Main Authors: Li, Xiaogang, Li, Butuo, Zeng, Haiyan, Wang, Shijiang, Sun, Xindong, Yu, Yishan, Wang, Linlin, Yu, Jinming
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.03.2019
• Subjects: albumin-to-alkaline phosphatase ratio; Biomarkers; Cancer therapies; Chemotherapy; Classification; Committees; Decision making; dynamically; limited stage small-cell lung cancer; Lung cancer; Medical prognosis; Metastasis; Patients; Phosphatase; prognostic; Prostate cancer; Radiation therapy; survival analysis; United States > US; China; prognostic; albumin-to-alkaline phosphatase ratio; limited stage small-cell lung cancer; survival analysis; dynamically
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2018-0818

To dynamically investigate the prognostic value of albumin-to-alkaline phosphatase ratio (AAPR) in limited stage small-cell lung cancer. The AAPR within 1 week before and after chemoradiation therapy (pre- and post-AAPR) was collected and analyzed. Patients with low pre- or post-AAPR had shorter overall survival and progression-free survival than the high groups (p-values all <0.05). Post-AAPR was an independent prognostic factor for progression-free survival (p = 0.007) and overall survival (p = 0.003). The integration of pre- or post-AAPR improved the prognostic ability of Tumor, Node, Metastasis stage alone (0.55-0.64 and 0.68, respectively). Post-AAPR is a reliable prognostic factor for limited stage small-cell lung cancer patients. The complementary value of AAPR to Tumor, Node, Metastasis stage is worth further validation in the future.